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IMMUNOREACTIVE endothelin (ETi) and atrial natriuretic
peptide (ANPi) blood levels were measured by radio-
immunoassay in patients with clinically defined sepsis.
The interaction between these two peptides and their
relation to circulatory shock and mortality were studied.
All septic patients (n 16) had significantly higher ETi
(22.3-- 11.1 pg/ml) and ANPi (398.3 4- 154.3 pg/ml) plas-
ma concentrations compared to control subjects (ETi,
4.1 4- 1.2; ANPi, 59.1 4- 14.8 pg/ml; n 13). ETi levels
followed the severity of illness according to the APACHE
II scoring system and were higher in patients who did not
survive. ETi levels were significantly higher in the pre-
sence of shock and bacteraemia. Furthermore, ETi corre-
lated well with plasma lactate (r 0.83, p < 0.05), but not
with renal function. ANPi levels did not show correlation
with any of these determinants. Serial blood sampling, six
consecutive days after admission, showed that ETi levels
gradually decreased in normotensive patients in contrast
to patients with septic shock. ANPi levels did not show
systematic changes in time, and no relationship was
observed between ETi and ANPi levels. These results
suggest that plasma ETi levels are indicative for disease
severity and might have prognostic significance. The role
of ANPi during sepsis remains to be eludicated.
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Introduction
Sepsis is a life threatening syndrome, mostly
induced by bacterial infections, which may be
complicated by shock, multiple organ failure, and
which carries a high mortality. The severity of the
disease is generally believed to be aggravated by the
release and activation of endogenous mediators in
response to bacterial products, like endotoxins. An
imbalance between vasodilating and vasoconstric-
tive factors may result in systemic vasodilatation,
and selective vasoconstriction in circumscript
vascular beds, as in the kidney.
Since it has become evident that endothelium
cells are capable of releasing vasoactive substances
that regulate vascular smooth muscle tone, these
substances have raised growing interest with regard
to the pathogenesis of the cardiovascular changes
induced by septic shock.’2 It is well documented
that endothelin (ET), a peptide produced and
secreted by the endothelium, has extremely potent
vasoconstrictor and vasopressor actions and de-
creases cardiac output and renal blood flow. 3’4
Recent studies showed a five- to ten-fold increase
of ET in the sepsis syndrome. 5’6 Atrial natriuretic
peptide (ANP), which is released by the cardiac atria
in response to a rise in blood pressure and volume,
induces a fall in blood pressure and a rise in renal
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blood flow. In this respect ANP is a potential
counter-reacting mediator of ET. ET has been
reported to directly or indirectly enhance the release
of ANP, while increased ANP release may act to
preserve the effects of ET on cardiovascular and
renal functions. 8’9
Theoretically, an imbalance in the release of these
two vasoactive peptides could induce or aggravate
the cardiovascular and renal changes characteristic
for sepsis. The aim of the present study was to test
this hypothesis. The profile of ET and ANP was
examined with regard to the severity of disease,
mortality and the presence of shock in patients with
sepsis. Also the relationship between these
vasoactive hormones and other determinants like
renal function and plasma lactate was studied.
Materials and Methods
Subjects: This study was performed in a total of 29
subject, with the approval of the hospital Medical
Ethics Committee.
Sixteen consecutive patients (ten female, six male;
mean age 72 years) with severe sepsis were studied.
The patients were admitted to the Intensive Care
Unit of our hospital during 1992. The criteria
for the diagnosis of sepsis were: hypothermia
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(<35.6C) or fever (>38.3C); tachycardia
> 90 beats/min) and tachypnoea > 20 breaths/min
or the requirement of mechanical ventilation),
as well as two of the following six signs of
inadequate organ function or perfusion: un-
explained metabolic acidosis (pH <7.3, base deficit
of >5 mmol/1, or an elevated lactate level);
hypoxaemia (pO2 < 10 kPa or ratio of the partial
pressure of oxygen to the fraction of inspired
oxygen <250); acute renal failure (urinary output
<0.5 ml/kg/h); coagulation abnormalities; acute
alteration in mental status; and cardiac index of
more than 4 1.min-1. m-2 of body surface area with
systemic vascular resistance of less than
800 dyn.s.cm-S.
1 Septic shock was defined as sepsis
with hypotension (systolic BP < 90 mmHg or a
reduction of >40 mmHg from baseline in the
absence of other causes for hypotension), despite
adequate fluid suppletion along with the presence
of perfusion abnormalities.1
In the septic patients, severity of illness on
admission was scored according to the Acute
Physiology and Chronic Health Evaluation
(APACHE I1) scoring system.
11 Systemic dynamics
were studied using a pulmonary artery catheter
(n 10). Patients were studied during the early
phase of sepsis/septic shock to minimize the
influence of therapeutic interventions on haemody-
namic and metabolic values.
The control group included 13 age- and
sex-matched healthy subjects. Patients with essential
hypertension, congestive heart failure, chronic renal
failure or liver cirrhosis were excluded from this
study.
Blood samples: On admission and with 8 h intervals
on day I and 2, and once daily on days 3 to 6, blood
samples were drawn by venipuncture or from an
indwelling venous catheter. Blood was collected
into pre-chilled tubes containing EDTA. Specimens
were immediately centrifuged at 4C and the plasma
was transferred to plastic tubes containing a
kallikrein inhibitor, aprotinin (200 KiU/ml blood,
Trasylol, Bayer, Leverkusen, Germany) and stored
at -15C. Blood samples of the control subjects
were collected between 08.00 and 10.00 h in the
supine position after 30 min rest.
Methods: Immunoreactive endothelin (ETi) con-
centrations were measured with a commercially
available radioimmunoassay (Nichols Institute, San
Juan Capistrano, CA, USA) after purification and
concentration of the plasma samples. Acidified
plasma samples (2 ml) were extracted by Sep Pak,
C18 reverse phase cartridges (Millipore Corp.,
Millford, MA, USA) and eluted with ethanol. Each
sample was evaporated to dryness under a stream
of nitrogen and the residue dissolved in assay buffer
and measured in duplicate. The results are expressed
as pg/ml ETi using endothelin-1 as standard. On
the molar basis, the antiserum showed 100%
crossreactivity with endothelin-1, 52% with en-
dothelin-2, 96% with endothelin-3, 7% with
big-endothelin and < 0.1% with other peptides
such as ANP, vasopressin or angiotensin II. The
detection limit of the assay (2 SD of the zero-point
binding) was 1 pg/ml (n--20). The interassay and
intra-assay coefficients of variation were 6.8%
(n= 12) and 4.5% (n= 20), respectively. The
normal value for ETi is 2.4-5.4 pg/ml.
Plasma immunoreactive ANP (ANPi) concentra-
tions were measured with a radioimmunoassay
(Nichols Institute, San Juan Capistrano, CA, USA).
Acidified plasma samples (0.5 ml) were extracted on
Sep Pak chromatography column, and measured in
duplicate. Results are expressed in pg/ml ANPi
using human alpha-ANP as standard. The anti-
serum has 100% crossreactivity with human
alpha-ANP, ANP 5-28 and ANP 7-28 calculated
on the molar basis and no crossreaction with MSH,
vasopressin, ACTH, endothelin and other ANP
fragments such as ANP 13-28 or ANP 1-11. The
detection limit of the assay was 7.5 pg/ml. The
interassay and intra-assay coefficients of variation
were 14.5% (n 8) and 7.7% (n 12), respectively.
The normal value for ANPi is 30-90 pg/ml.
24-h urine was collected for 6 days for
determination of creatinine clearance.
Statistical analysis" Values are expressed as mean
_+SD. Linear regression analysis was used to
determine correlations between plasma ETi and
ANPi concentrations and other variables. Statistical
analysis was performed by Student’s t-test;p < 0.05
was considered a significant difference.
Results
A group of 16 patients with clinically defined
sepsis was studied. A shock state, as defined above,
was confirmed in six patients. Median APACHE II
score on admission was 28 and ranged from 18 to
47. Bacteraemia was confirmed by blood cultures in
seven patients. Six patients died, ofwhom four died
within 48 h after admission. The comparison
between survivors and nonsurvivors is shown in
Table 1. As expected, the APACHE II score in
patients who died was higher than in survivors. The
survivors showed lactate levels three times lower
than the nonsurvivors (2.7 mmol/1 vs. 9.9 mmol/1,
p < 0.01). On admission, all septic patients had
increased ETi and ANPi concentrations compared
to age- and sex-matched controls, mean values
22.3 _-+ 11.1 pg/ml and 398.3 _q-154.3pg/ml, re-
spectively (Table 2). The ETi levels followed
the severity of illness and were higher in patients
who died than in survivors" 28.6 + 13.3 vs.
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Table 1. Data from the 16 patients according to survival and
mortality
Survivors Nonsurvivors
Number 10 6
Mean age (years) 71.5 + 13 68 +_ 24
Bacteraemia 5 2
Shock 2 4
APACHE II 24 + 7 31 4- 9*
Plasma lactate (mmol/I) 2.7 4- 2 9.9 _+ 9*
Plasma creatinine (/mol/I) 214 4- 84 232 + 135
ETi level (pg/ml) 18.5 8.0 28.6 + 13.3*
ANPi level (pg/ml) 419.6 114.2 362.8 __+ 213.4
Values represent the mean 4- SD. Statistical significance by
Student’s t-test: *p < 0.05 survivors vs. nonsurvivors.
Table 2. Immunoreactive endothelin (ETi) and atrial natriuretic
peptide (ANPi) plasma concentrations in patients with severe
sepsis and age- and sex-matched control subjects in relation to
shock and mortality
n ETi (pg/ml) ANPi (pg/ml)
Controls 13 4.1 4- 1.2 59.1 ___
14.8
All patients 16 22.3 _+ 11.1 398.3 4- 154.3*
Sepsis 10 14.1 _+ 2.9 366.1 4- 122.0
Septic shock 6 27.3 _+ 11.3"* 417.7 4- 174.1
Survivors 10 18.5 _+ 8.0 419.6 4- 114.2
Nonsurvivors 6 28.6 4- 13.3"** 362.8 4- 213.4
Values represent the mean 4- SD of the highest concentrations
measured during the first 48 h after admission. Statistical
significance by Student’s t-test p<0.05" *all patients vs.
controls" **septic patients without shock vs. those with shock;
***survivors vs. nonsurvivors, n number of subjects.
18.5 8pg/ml. In our patients, there was a
significant linear correlation between ETi levels on
admission and the APACHE II score (r--0.57,
p < 0.05). Furthermore, linear regression demon-
strated a significant correlation between ETi and
plasma lactate levels (r-0.83, p < 0.05). No
correlation between ETi levels and serum creatinine
or creatinine clearance was found. In contrast,
ANPi levels did not dier significantly between the
various subgroups (Table 2), and no correlation was
found between ANPi blood levels and other
determinants.
ETi levels were significantly higher in the
presence of shock with positive bloodcultures,
whereas the plasma ANPi levels were not different
when related to the presence or absence of shock
and bacteraemia (Table 3).
ETi levels in patients with septic shock appeared
to be significantly (p < 0.01) higher than in
normotensive septic patients, again in contrast to
ANPi levels. Furthermore, we also found a negative
correlation between ETi and mean arterial pressure
(r -0.47, p < 0.05).
In eleven patients we tested serial samples during
a period of six consecutive days after admission.
The evolution of ETi plasma levels over time is
shown in Fig. 1. In the group of patients with septic
shock ETi levels remained stable in most patients,
in contrast to the group of normotensive septic
patients in which a significant decrease was noted
(day 1, 13.9 _--k 3.1 pg/ml vs. day 6, 8.3 -k 2.3 pg/ml,
p < 0.05). When looked upon longitudinally ANPi
levels showed no trend or change (results not
shown).
Discussion
The present study shows that patients with
sepsis exhibit at the moment of admission markedly
increased plasma levels of ETi and that the height
of these levels is correlated with the severity of the
illness, according to the APACHE II scoring
system.
11 Moreover, nonsurvivors had higher ETi
levels than survivors. These data are in agreement
with the findings of Pittet et al. in eleven patients
and of Weitzberg et al.
6 in six patients with sepsis.
Recent animal studies showed also an increase of
ETi during endotoxaemia.12-14 ET is a ten-fold
more potent vasoconstrictor than angiotensin II
and has extremely long-lasting pressor effects.4
Severe sepsis is characterized by an increase
in cardiac output, general vasodilatation and/or
hypotension. These cardiovascular changes are
mediated by endogenous vasodilatators like nitric
oxide and ANP and vasoconstrictors like ET. A
close interaction is present between these vasoactive
Table 3. Immunoreactive endotheline (ETi) and atrial natriuretic peptide (ANPi)
plasma concentrations in septic patients according to the presence or absence of
bacteraemia and shock
Bacteraemia Shock n APACHE II ETI (pg/ml) ANPi (pg/ml)
2(0) 21 _+ 4 15.3 4- 2.1 358 _+ 200
+ 4(0) 25 4- 6 14.3 _+ 3.1 370 + 107
+ 7 (4) 31 ___
6 20.7 _+ 3.7 436 + 167
+ + 3(2) 35 _+ 10 43.7 _+ 6.1" 373 4- 219
Values represent the mean 4- SD of the highest ETi and ANPi concentrations during
the first 48 h after admission. Statistical significance by Student’s t-test p < 0.05"
*septic shock patients with bacteraemia vs. those without bacteraemia, n number of
patients, deaths in parentheses.
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FIG. 1. Evolution of immunoreactive endothelin (ETi) plasma levels in
time in normotensive septic patients (upper panel) and in patients with
septic shock (lower panel).
substances; ET stimulates nitric oxide production,
15
and therefore possibly contributing to the vascular
hyporesponsiveness found in septic shock,
16 while
nitric oxide inhibits ET release.7 Despite these
changes, plasma ETi levels are increased in septic
patients, suggesting that ETi possibly acts as a local
regulatory peptide leading to (selective) vasocon-
striction. Moreover, ETi levels correlated well with
symptoms of shock, and there was an inverse
relationship with mean arterial pressure. Possibly,
ETi is no longer effective in controlling systemic
arterial pressure under these pathological condi-
tions. We also found a significant correlation
between ETi and plasma lactate levels, reflecting
the severity of the shock state. No relation was
found between ETi and renal function, excluding
renal failure as the cause for the increased ETi levels
observed in our patients.
18
To the authors’ knowledge no data exist about
the plasma levels of ANPi in patients with sepsis.
Eison et al.
19 observed an increase of ANPi in
twelve patients with adult respiratory distress
syndrome. A preliminary, study of Mitaka et al.2
reported similar findings in patients with respir-
atory failure associated with sepsis. In an ovine
model of endotoxaemia a 13-fold increase or ANPi
was found, leading to increased diuresis and
natriuresis.
ET has been reported to enhance ANP release
and because ANP by its vasodilatory and natriuretic
properties counteracts ET, we expected increased
ANPi levels in patients with sepsis.<9 Our findings
were in accordance with this supposition, as plasma
levels of ANPi appeared significantly elevated in all
16 patients. However, in contrast to ETi, the ANPi
levels showed no relation with the severity of the
sepsis, neither with the presence of shock.
It is generally accepted that ET elevation is due
to damage of the endothelium,3’4 the rise of ANPi
may be an expression of many different trigger
mechanisms like atrial stretch, changes in in-
travascular volume, tachycardia, adrenal and
pituitary gland hormones.7 The complete lack of
correlation between ETi levels and ANPi levels
exclude ET stimulation as the principal cause of
increased ANPi in patients with sepsis.
The prolonged elevation of ETi we observed
during 6 consecutive days poses the question of
whether this is the result of stimulated continuous
synthesis or if it is a reflection of reduced
elimination of ET. The observed longstanding high
ETi levels, especially in patients with septic shock,
certainly play an essential part in the evolution and
severity of this disease.
In conclusion, the present observations demon-
strate that ETi concentrations are correlated with
the severity and final outcome of sepsis and that
ANPi concentrations are not. ETi levels are
associated with the presence of a shock state and
with the degree of tissue ischaemia reflected by
plasma lactate concentrations. Further clinical
studies are needed to clarify the precise role of ET
in the pathogenesis and course of sepsis.
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